 | • レポートコード：MRC308GR11637 • 出版社/出版日：GlobalInfoResearch / 2023年8月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
GlobalInfoResearchの最新の調査によると、世界のカンナビノイド由来医薬品の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界のカンナビノイド由来医薬品市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。
市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。
本レポートの主な目的は次のとおりです。
– 世界および主要国の市場機会の規模を決定するため
– カンナビノイド由来医薬品の成長可能性を評価するため
– 各製品および最終用途市場の将来の成長を予測するため
– 市場に影響を与える競争要因を評価するため
カンナビノイド由来医薬品市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。
種類別セグメント
・カンナビノイド受容体型1 （CB1）、カンナビノイド受容体型2 （CB2）、その他
用途別セグメント
・てんかん、片頭痛、多発性硬化症、その他
主要な市場プレーヤー
・Cara Therapeutics Inc、Arena Pharmaceuticals、Cannabics Pharmaceuticals Inc、Echo Pharmaceuticals、Gw Pharmaceuticals、Inmed Pharmaceuticals、Insys Therapeutics Inc、Larapharm、Mgc Pharmaceuticals Ltd、One World Cannabis、Orpheus Medica、Receptor Life Sciences、Respirerx Pharmaceuticals、Tetra Bio-Pharma、Cardiol Therapeutics、United Cannabis Corporation、Zynerba Pharmaceuticals
地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）
本調査レポートの内容は計15章あります。
・第1章では、カンナビノイド由来医薬品製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なカンナビノイド由来医薬品メーカーの企業概要、2019年～2022年までのカンナビノイド由来医薬品の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なカンナビノイド由来医薬品メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別カンナビノイド由来医薬品の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までのカンナビノイド由来医薬品の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのカンナビノイド由来医薬品市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、およびカンナビノイド由来医薬品の産業チェーンを掲載しています。
・第14、15章では、カンナビノイド由来医薬品の販売チャネル、販売業者、顧客、調査結果について説明します。
***** 目次(一部) *****
・市場概要
– カンナビノイド由来医薬品の概要
– 種類別分析（2018年vs2022年vs2029年）：カンナビノイド受容体型1 （CB1）、カンナビノイド受容体型2 （CB2）、その他
– 用途別分析（2018年vs2022年vs2029年）：てんかん、片頭痛、多発性硬化症、その他
– 世界のカンナビノイド由来医薬品市場規模・予測
– 世界のカンナビノイド由来医薬品生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Cara Therapeutics Inc、Arena Pharmaceuticals、Cannabics Pharmaceuticals Inc、Echo Pharmaceuticals、Gw Pharmaceuticals、Inmed Pharmaceuticals、Insys Therapeutics Inc、Larapharm、Mgc Pharmaceuticals Ltd、One World Cannabis、Orpheus Medica、Receptor Life Sciences、Respirerx Pharmaceuticals、Tetra Bio-Pharma、Cardiol Therapeutics、United Cannabis Corporation、Zynerba Pharmaceuticals
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：カンナビノイド受容体型1 （CB1）、カンナビノイド受容体型2 （CB2）、その他
・用途別分析2018年-2029年：てんかん、片頭痛、多発性硬化症、その他
・カンナビノイド由来医薬品の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・カンナビノイド由来医薬品のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・カンナビノイド由来医薬品のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・カンナビノイド由来医薬品の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・カンナビノイド由来医薬品の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
1 Market Overview
1.1 Product Overview and Scope of Cannabinoid Derived Pharmaceutical
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Cannabinoid Derived Pharmaceutical Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Cannabinoid Receptor Type 1 (CB1)
1.3.3 Cannabinoid Receptor Type 2 (CB2)
1.3.4 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Cannabinoid Derived Pharmaceutical Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Epilepsy
1.4.3 Migraine
1.4.4 Multiple Sclerosis
1.4.5 Others
1.5 Global Cannabinoid Derived Pharmaceutical Market Size & Forecast
1.5.1 Global Cannabinoid Derived Pharmaceutical Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Cannabinoid Derived Pharmaceutical Sales Quantity (2018-2029)
1.5.3 Global Cannabinoid Derived Pharmaceutical Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Cara Therapeutics Inc
2.1.1 Cara Therapeutics Inc Details
2.1.2 Cara Therapeutics Inc Major Business
2.1.3 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Product and Services
2.1.4 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Cara Therapeutics Inc Recent Developments/Updates
2.2 Arena Pharmaceuticals
2.2.1 Arena Pharmaceuticals Details
2.2.2 Arena Pharmaceuticals Major Business
2.2.3 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
2.2.4 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Arena Pharmaceuticals Recent Developments/Updates
2.3 Cannabics Pharmaceuticals Inc
2.3.1 Cannabics Pharmaceuticals Inc Details
2.3.2 Cannabics Pharmaceuticals Inc Major Business
2.3.3 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Product and Services
2.3.4 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Cannabics Pharmaceuticals Inc Recent Developments/Updates
2.4 Echo Pharmaceuticals
2.4.1 Echo Pharmaceuticals Details
2.4.2 Echo Pharmaceuticals Major Business
2.4.3 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
2.4.4 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Echo Pharmaceuticals Recent Developments/Updates
2.5 Gw Pharmaceuticals
2.5.1 Gw Pharmaceuticals Details
2.5.2 Gw Pharmaceuticals Major Business
2.5.3 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
2.5.4 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Gw Pharmaceuticals Recent Developments/Updates
2.6 Inmed Pharmaceuticals
2.6.1 Inmed Pharmaceuticals Details
2.6.2 Inmed Pharmaceuticals Major Business
2.6.3 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
2.6.4 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Inmed Pharmaceuticals Recent Developments/Updates
2.7 Insys Therapeutics Inc
2.7.1 Insys Therapeutics Inc Details
2.7.2 Insys Therapeutics Inc Major Business
2.7.3 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Product and Services
2.7.4 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Insys Therapeutics Inc Recent Developments/Updates
2.8 Larapharm
2.8.1 Larapharm Details
2.8.2 Larapharm Major Business
2.8.3 Larapharm Cannabinoid Derived Pharmaceutical Product and Services
2.8.4 Larapharm Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Larapharm Recent Developments/Updates
2.9 Mgc Pharmaceuticals Ltd
2.9.1 Mgc Pharmaceuticals Ltd Details
2.9.2 Mgc Pharmaceuticals Ltd Major Business
2.9.3 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Product and Services
2.9.4 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Mgc Pharmaceuticals Ltd Recent Developments/Updates
2.10 One World Cannabis
2.10.1 One World Cannabis Details
2.10.2 One World Cannabis Major Business
2.10.3 One World Cannabis Cannabinoid Derived Pharmaceutical Product and Services
2.10.4 One World Cannabis Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 One World Cannabis Recent Developments/Updates
2.11 Orpheus Medica
2.11.1 Orpheus Medica Details
2.11.2 Orpheus Medica Major Business
2.11.3 Orpheus Medica Cannabinoid Derived Pharmaceutical Product and Services
2.11.4 Orpheus Medica Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Orpheus Medica Recent Developments/Updates
2.12 Receptor Life Sciences
2.12.1 Receptor Life Sciences Details
2.12.2 Receptor Life Sciences Major Business
2.12.3 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Product and Services
2.12.4 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Receptor Life Sciences Recent Developments/Updates
2.13 Respirerx Pharmaceuticals
2.13.1 Respirerx Pharmaceuticals Details
2.13.2 Respirerx Pharmaceuticals Major Business
2.13.3 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
2.13.4 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Respirerx Pharmaceuticals Recent Developments/Updates
2.14 Tetra Bio-Pharma
2.14.1 Tetra Bio-Pharma Details
2.14.2 Tetra Bio-Pharma Major Business
2.14.3 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Product and Services
2.14.4 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Tetra Bio-Pharma Recent Developments/Updates
2.15 Cardiol Therapeutics
2.15.1 Cardiol Therapeutics Details
2.15.2 Cardiol Therapeutics Major Business
2.15.3 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Product and Services
2.15.4 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Cardiol Therapeutics Recent Developments/Updates
2.16 United Cannabis Corporation
2.16.1 United Cannabis Corporation Details
2.16.2 United Cannabis Corporation Major Business
2.16.3 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Product and Services
2.16.4 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 United Cannabis Corporation Recent Developments/Updates
2.17 Zynerba Pharmaceuticals
2.17.1 Zynerba Pharmaceuticals Details
2.17.2 Zynerba Pharmaceuticals Major Business
2.17.3 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
2.17.4 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Zynerba Pharmaceuticals Recent Developments/Updates
3 Competitive Environment: Cannabinoid Derived Pharmaceutical by Manufacturer
3.1 Global Cannabinoid Derived Pharmaceutical Sales Quantity by Manufacturer (2018-2023)
3.2 Global Cannabinoid Derived Pharmaceutical Revenue by Manufacturer (2018-2023)
3.3 Global Cannabinoid Derived Pharmaceutical Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Cannabinoid Derived Pharmaceutical by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Cannabinoid Derived Pharmaceutical Manufacturer Market Share in 2022
3.4.2 Top 6 Cannabinoid Derived Pharmaceutical Manufacturer Market Share in 2022
3.5 Cannabinoid Derived Pharmaceutical Market: Overall Company Footprint Analysis
3.5.1 Cannabinoid Derived Pharmaceutical Market: Region Footprint
3.5.2 Cannabinoid Derived Pharmaceutical Market: Company Product Type Footprint
3.5.3 Cannabinoid Derived Pharmaceutical Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Cannabinoid Derived Pharmaceutical Market Size by Region
4.1.1 Global Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2029)
4.1.2 Global Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2029)
4.1.3 Global Cannabinoid Derived Pharmaceutical Average Price by Region (2018-2029)
4.2 North America Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)
4.3 Europe Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)
4.4 Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)
4.5 South America Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)
4.6 Middle East and Africa Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
5.2 Global Cannabinoid Derived Pharmaceutical Consumption Value by Type (2018-2029)
5.3 Global Cannabinoid Derived Pharmaceutical Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
6.2 Global Cannabinoid Derived Pharmaceutical Consumption Value by Application (2018-2029)
6.3 Global Cannabinoid Derived Pharmaceutical Average Price by Application (2018-2029)
7 North America
7.1 North America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
7.2 North America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
7.3 North America Cannabinoid Derived Pharmaceutical Market Size by Country
7.3.1 North America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2029)
7.3.2 North America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
8.2 Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
8.3 Europe Cannabinoid Derived Pharmaceutical Market Size by Country
8.3.1 Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2029)
8.3.2 Europe Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Cannabinoid Derived Pharmaceutical Market Size by Region
9.3.1 Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
10.2 South America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
10.3 South America Cannabinoid Derived Pharmaceutical Market Size by Country
10.3.1 South America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2029)
10.3.2 South America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Cannabinoid Derived Pharmaceutical Market Size by Country
11.3.1 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Cannabinoid Derived Pharmaceutical Market Drivers
12.2 Cannabinoid Derived Pharmaceutical Market Restraints
12.3 Cannabinoid Derived Pharmaceutical Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Cannabinoid Derived Pharmaceutical and Key Manufacturers
13.2 Manufacturing Costs Percentage of Cannabinoid Derived Pharmaceutical
13.3 Cannabinoid Derived Pharmaceutical Production Process
13.4 Cannabinoid Derived Pharmaceutical Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Cannabinoid Derived Pharmaceutical Typical Distributors
14.3 Cannabinoid Derived Pharmaceutical Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table 1. Global Cannabinoid Derived Pharmaceutical Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Cannabinoid Derived Pharmaceutical Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Cara Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 4. Cara Therapeutics Inc Major Business
Table 5. Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Product and Services
Table 6. Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Cara Therapeutics Inc Recent Developments/Updates
Table 8. Arena Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. Arena Pharmaceuticals Major Business
Table 10. Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 11. Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Arena Pharmaceuticals Recent Developments/Updates
Table 13. Cannabics Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 14. Cannabics Pharmaceuticals Inc Major Business
Table 15. Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Product and Services
Table 16. Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Cannabics Pharmaceuticals Inc Recent Developments/Updates
Table 18. Echo Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Echo Pharmaceuticals Major Business
Table 20. Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 21. Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Echo Pharmaceuticals Recent Developments/Updates
Table 23. Gw Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Gw Pharmaceuticals Major Business
Table 25. Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 26. Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Gw Pharmaceuticals Recent Developments/Updates
Table 28. Inmed Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 29. Inmed Pharmaceuticals Major Business
Table 30. Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 31. Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Inmed Pharmaceuticals Recent Developments/Updates
Table 33. Insys Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 34. Insys Therapeutics Inc Major Business
Table 35. Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Product and Services
Table 36. Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Insys Therapeutics Inc Recent Developments/Updates
Table 38. Larapharm Basic Information, Manufacturing Base and Competitors
Table 39. Larapharm Major Business
Table 40. Larapharm Cannabinoid Derived Pharmaceutical Product and Services
Table 41. Larapharm Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Larapharm Recent Developments/Updates
Table 43. Mgc Pharmaceuticals Ltd Basic Information, Manufacturing Base and Competitors
Table 44. Mgc Pharmaceuticals Ltd Major Business
Table 45. Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Product and Services
Table 46. Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Mgc Pharmaceuticals Ltd Recent Developments/Updates
Table 48. One World Cannabis Basic Information, Manufacturing Base and Competitors
Table 49. One World Cannabis Major Business
Table 50. One World Cannabis Cannabinoid Derived Pharmaceutical Product and Services
Table 51. One World Cannabis Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. One World Cannabis Recent Developments/Updates
Table 53. Orpheus Medica Basic Information, Manufacturing Base and Competitors
Table 54. Orpheus Medica Major Business
Table 55. Orpheus Medica Cannabinoid Derived Pharmaceutical Product and Services
Table 56. Orpheus Medica Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Orpheus Medica Recent Developments/Updates
Table 58. Receptor Life Sciences Basic Information, Manufacturing Base and Competitors
Table 59. Receptor Life Sciences Major Business
Table 60. Receptor Life Sciences Cannabinoid Derived Pharmaceutical Product and Services
Table 61. Receptor Life Sciences Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Receptor Life Sciences Recent Developments/Updates
Table 63. Respirerx Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 64. Respirerx Pharmaceuticals Major Business
Table 65. Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 66. Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Respirerx Pharmaceuticals Recent Developments/Updates
Table 68. Tetra Bio-Pharma Basic Information, Manufacturing Base and Competitors
Table 69. Tetra Bio-Pharma Major Business
Table 70. Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Product and Services
Table 71. Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Tetra Bio-Pharma Recent Developments/Updates
Table 73. Cardiol Therapeutics Basic Information, Manufacturing Base and Competitors
Table 74. Cardiol Therapeutics Major Business
Table 75. Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Product and Services
Table 76. Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Cardiol Therapeutics Recent Developments/Updates
Table 78. United Cannabis Corporation Basic Information, Manufacturing Base and Competitors
Table 79. United Cannabis Corporation Major Business
Table 80. United Cannabis Corporation Cannabinoid Derived Pharmaceutical Product and Services
Table 81. United Cannabis Corporation Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. United Cannabis Corporation Recent Developments/Updates
Table 83. Zynerba Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 84. Zynerba Pharmaceuticals Major Business
Table 85. Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Product and Services
Table 86. Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Zynerba Pharmaceuticals Recent Developments/Updates
Table 88. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 89. Global Cannabinoid Derived Pharmaceutical Revenue by Manufacturer (2018-2023) & (USD Million)
Table 90. Global Cannabinoid Derived Pharmaceutical Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 91. Market Position of Manufacturers in Cannabinoid Derived Pharmaceutical, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 92. Head Office and Cannabinoid Derived Pharmaceutical Production Site of Key Manufacturer
Table 93. Cannabinoid Derived Pharmaceutical Market: Company Product Type Footprint
Table 94. Cannabinoid Derived Pharmaceutical Market: Company Product Application Footprint
Table 95. Cannabinoid Derived Pharmaceutical New Market Entrants and Barriers to Market Entry
Table 96. Cannabinoid Derived Pharmaceutical Mergers, Acquisition, Agreements, and Collaborations
Table 97. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2023) & (K Units)
Table 98. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2024-2029) & (K Units)
Table 99. Global Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2023) & (USD Million)
Table 100. Global Cannabinoid Derived Pharmaceutical Consumption Value by Region (2024-2029) & (USD Million)
Table 101. Global Cannabinoid Derived Pharmaceutical Average Price by Region (2018-2023) & (US$/Unit)
Table 102. Global Cannabinoid Derived Pharmaceutical Average Price by Region (2024-2029) & (US$/Unit)
Table 103. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 104. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 105. Global Cannabinoid Derived Pharmaceutical Consumption Value by Type (2018-2023) & (USD Million)
Table 106. Global Cannabinoid Derived Pharmaceutical Consumption Value by Type (2024-2029) & (USD Million)
Table 107. Global Cannabinoid Derived Pharmaceutical Average Price by Type (2018-2023) & (US$/Unit)
Table 108. Global Cannabinoid Derived Pharmaceutical Average Price by Type (2024-2029) & (US$/Unit)
Table 109. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Global Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 111. Global Cannabinoid Derived Pharmaceutical Consumption Value by Application (2018-2023) & (USD Million)
Table 112. Global Cannabinoid Derived Pharmaceutical Consumption Value by Application (2024-2029) & (USD Million)
Table 113. Global Cannabinoid Derived Pharmaceutical Average Price by Application (2018-2023) & (US$/Unit)
Table 114. Global Cannabinoid Derived Pharmaceutical Average Price by Application (2024-2029) & (US$/Unit)
Table 115. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 116. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 117. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 118. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 119. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2023) & (K Units)
Table 120. North America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2024-2029) & (K Units)
Table 121. North America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2023) & (USD Million)
Table 122. North America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2024-2029) & (USD Million)
Table 123. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 124. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 125. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 126. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 127. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2023) & (K Units)
Table 128. Europe Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2024-2029) & (K Units)
Table 129. Europe Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2023) & (USD Million)
Table 130. Europe Cannabinoid Derived Pharmaceutical Consumption Value by Country (2024-2029) & (USD Million)
Table 131. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 132. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 133. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 134. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 135. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2023) & (K Units)
Table 136. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2024-2029) & (K Units)
Table 137. Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2023) & (USD Million)
Table 138. Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value by Region (2024-2029) & (USD Million)
Table 139. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 140. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 141. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 142. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 143. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2018-2023) & (K Units)
Table 144. South America Cannabinoid Derived Pharmaceutical Sales Quantity by Country (2024-2029) & (K Units)
Table 145. South America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2018-2023) & (USD Million)
Table 146. South America Cannabinoid Derived Pharmaceutical Consumption Value by Country (2024-2029) & (USD Million)
Table 147. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2018-2023) & (K Units)
Table 148. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Type (2024-2029) & (K Units)
Table 149. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2018-2023) & (K Units)
Table 150. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Application (2024-2029) & (K Units)
Table 151. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2018-2023) & (K Units)
Table 152. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity by Region (2024-2029) & (K Units)
Table 153. Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value by Region (2018-2023) & (USD Million)
Table 154. Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value by Region (2024-2029) & (USD Million)
Table 155. Cannabinoid Derived Pharmaceutical Raw Material
Table 156. Key Manufacturers of Cannabinoid Derived Pharmaceutical Raw Materials
Table 157. Cannabinoid Derived Pharmaceutical Typical Distributors
Table 158. Cannabinoid Derived Pharmaceutical Typical Customers
List of Figures
Figure 1. Cannabinoid Derived Pharmaceutical Picture
Figure 2. Global Cannabinoid Derived Pharmaceutical Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Type in 2022
Figure 4. Cannabinoid Receptor Type 1 (CB1) Examples
Figure 5. Cannabinoid Receptor Type 2 (CB2) Examples
Figure 6. Others Examples
Figure 7. Global Cannabinoid Derived Pharmaceutical Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Application in 2022
Figure 9. Epilepsy Examples
Figure 10. Migraine Examples
Figure 11. Multiple Sclerosis Examples
Figure 12. Others Examples
Figure 13. Global Cannabinoid Derived Pharmaceutical Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Cannabinoid Derived Pharmaceutical Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Cannabinoid Derived Pharmaceutical Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Cannabinoid Derived Pharmaceutical Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Cannabinoid Derived Pharmaceutical by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Cannabinoid Derived Pharmaceutical Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Cannabinoid Derived Pharmaceutical Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Cannabinoid Derived Pharmaceutical Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Cannabinoid Derived Pharmaceutical Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Region (2018-2029)
Figure 55. China Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Cannabinoid Derived Pharmaceutical Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Cannabinoid Derived Pharmaceutical Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Cannabinoid Derived Pharmaceutical Market Drivers
Figure 76. Cannabinoid Derived Pharmaceutical Market Restraints
Figure 77. Cannabinoid Derived Pharmaceutical Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Cannabinoid Derived Pharmaceutical in 2022
Figure 80. Manufacturing Process Analysis of Cannabinoid Derived Pharmaceutical
Figure 81. Cannabinoid Derived Pharmaceutical Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source